Last updated: January 14, 2026
Onyx is a liquid embolic system developed by Micro Therapeutics, Inc. It comprises ethylene-vinyl alcohol copolymer (EVOH) made from 48 mol/L ethylene and 52 mol/L vinyl alcohol, dissolved in dimethyl-sulfoxide (DMSO) and combined with 35% weight per volume micronized tantalum powder for radiopacity. Primarily used globally for treating cerebral and spinal arteriovenous malformations (AVMs), it also has applications in hypervascular tumors, peripheral AVMs, arteriovenous fistulas (AVFs), and endoleak treatment.
| File Name | Type | Permissions | Changed Date | Date | Size |
|---|
Type I: Inadequate seal (Ia: proximal, Ib: distal)
Type II: Retrograde flow from side branches of an aortic aneurysm (IIa: single vessel, IIb: two vessels or more)
Type III: Inadequate joint between the stent-grafts or damage to the stent-graft (IIIa: junctional separation of the modular components, IIIb: fractures or holes involving the endograft)
Type IV: Porosity of the stent-graft
Type V: Endotension; gradual enlargement without apparent endoleaks
Type I: Inadequate seal (Ia: proximal, Ib: distal)
Type II: Retrograde flow from side branches of an aortic aneurysm (IIa: single vessel, IIb: two vessels or more)
Type III: Inadequate joint between the stent-grafts or damage to the stent-graft (IIIa: junctional separation of the modular components, IIIb: fractures or holes involving the endograft)
Type IV: Porosity of the stent-graft
Type V: Endotension; gradual enlargement without apparent endoleaks
Write your text here